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Abstract
Background: Systemic lupus erythematosus (SLE) patients have a striking increase in cardiovascular (CV) comorbidity not
fully explained by the Framingham risk score. Recent evidence from in vitro studies suggests that type I interferons (IFN)
could promote premature CV disease (CVD) in SLE. We assessed the association of type I IFN signatures with functional and
anatomical evidence of vascular damage, and with biomarkers of CV risk in a cohort of lupus patients without overt CVD.
Methodology/Principal Findings: Serum type I IFN activity (induction of five IFN-inducible genes; IFIGs) from 95 SLE patient
and 38 controls was quantified by real-time PCR. Flow mediated dilatation (FMD) of the brachial artery and carotid intima
media thickness (CIMT) were quantified by ultrasound, and coronary calcification by computed tomography. Serum vascular
biomarkers were measured by ELISA. We evaluated the effect of type I IFNs on FMD, CIMT and coronary calcification by first
applying principal components analysis to combine data from five IFIGs into summary components that could be
simultaneously modeled. Three components were derived explaining 97.1% of the total IFIG variation. Multivariable linear
regression was utilized to investigate the association between the three components and other covariates, with the
outcomes of FMD and CIMT; zero-inflated Poisson regression was used for modeling of coronary calcification. After
controlling for traditional CV risk factors, enhanced serum IFN activity was significantly associated with decreased
endothelial function in SLE patients and controls (p,0.05 for component 3), increased CIMT among SLE patients (p,0.01 for
components 1 and 2), and severity of coronary calcification among SLE patients (p,0.001 for component 3).
Conclusions: Type I IFNs are independently associated with atherosclerosis development in lupus patients without history
of overt CVD and after controlling for Framingham risk factors. This study further supports the hypothesis that type I IFNs
promote premature vascular damage in SLE.
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Introduction
Systemic lupus erythematosus (SLE) is associated with strikingly
high rates of premature cardiovascular disease (CVD) [1,2,3,4]. A
significant proportion of patients displays subclinical vascular
disease [5,6,7] with premature and more severe coronary artery
calcification and carotid intima media thickness (CIMT) and
plaque [8,9,10]. Framingham risk factors are considered less
important CVD predictors than active SLE [11]. While lupus
immune dysregulation may play a dominant role in atherogenesis,
the pathways implicated in accelerated CVD remain unclear.
As a potential mechanism explaining this enhanced risk, we
reported that SLE patients develop a profound imbalance between
endothelial cell (EC) damage and repair, manifested by increased
circulating apoptotic ECs [5], decreased numbers and function of
bone marrow derived endothelial progenitor cells (EPCs) and
circulating angiogenic cells (CACs), and blunted synthesis of
proangiogenic factors [12,13]. Increased circulating apoptotic ECs
in SLE correlates with endothelial dysfunction and tissue factor
(TF) generation [5]. Similar EPC/CAC abnormalities have been
identified as CVD risk factors in various diseases and in the
general population [14,15,16].
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in SLE [17] and their increased levels are reported in lupus blood
and tissues [18,19,20]. We previously reported that type I IFNs
induce abnormal EPC/CAC function in SLE. IFN-a promotes
EPC/CAC apoptosis, skews CACs toward nonangiogenic pheno-
types and represses proangiogenic molecule synthesis, including
VEGF and IL-1b [13,21]. Indeed, type I IFN pathway neutral-
ization restores lupus EPC/CAC function [12]. Lupus EPC
depletion and impaired arterial tone correlate with type I IFNs
[22]. A proinflammatory subset of lupus neutrophils synthesizes
increased type I IFNs and their depletion results in vasculogenesis
improvements [23]. Further, IFN-a-dependent murine lupus
models display endothelial dysfunction and aberrant vasculogen-
esis [24]. Recent evidence indicates that type I IFNs may also
promote atherothrombosis by inducing a platelet proinflammatory
phenotype [25] and foam cell formation in vitro [26]. These
observations support a role for type I IFNs in lupus premature
CVD.
The purpose of this study was to further characterize the role of
type I IFNs in endothelial dysfunction and CV risk in lupus. To
this end, we studied a cohort of SLE patients and controls without
CVD history and with low burden of traditional CV risk factors, to
examine the associations between serum type I IFN activity and
various markers of vascular damage and atherosclerotic risk.
Methods
Objectives
The primary objective of this study was to examine the
associations between type I IFNs and three measures of subclinical
CVD – flow-mediated dilatation (FMD) of the brachial artery to
assess endothelium-dependent vasorelaxation, carotid intima
media thickness (CIMT), and coronary calcification, to assess
subclinical atherosclerosis. Our hypothesis was that enhanced type
I IFN activity would be associated with depressed FMD, and
increased CIMT and coronary calcification, thereby promoting
enhanced CV risk.
Ethics
This study was approved by the University of Michigan’s
Institutional Review Board. Study participants gave written
informed consent.
Participants
SLE patients meeting the revised American College of
Rheumatology (ACR) classification criteria for SLE [27] were
recruited from the Michigan Lupus Cohort [28], and were eligible
for inclusion if they were ,55 years of age at baseline and had no
previous history of overt CV events. Patients were excluded if they
were smokers (currently or within the previous 6 months), had
diabetes, were pregnant, had a current infection, or were taking
more than one antihypertensive in addition to a diuretic. Controls
fulfilling the same eligibility criteria were recruited from the
University of Michigan Women’s Health Registry [29], and were
frequency matched by age and sex to the SLE patients.
Description of Procedures Undertaken
SLE-specific measures. SLE activity was prospectively
measured with the SLE Disease Activity Index (SLEDAI) and
accumulated damage by the Systemic Lupus International
Collaborating Clinics/ACR (SLICC/ACR) Damage Index
[30,31].
Vascular function assessment. FMD was quantified by
ultrasound as previously described [5,28]. Brachial artery diameter
(BAD) baseline measurements were obtained. A blood pressure
(BP) cuff was inflated to 50 mmHg above participant’s systolic BP
over proximal portion of right forearm for 4 minutes. FMD was
determined 1 minute after cuff release. Image acquisition was
gated to EKG’s R wave. The endpoint was the percentage change
in mean BAD in response to reactive hyperemia (FMD).
Carotid ultrasound. CIMT was assessed by B-mode ultra-
sonography. One centimeter segments of bilateral common
carotid arteries, carotid bulbs, and distal internal carotid arteries
were scanned. Images were obtained of the near or far wall of each
arterial segment per standardized procedures. Intima-medial
complex thickness was calculated as the distance from leading
edge of first echogenic line to second echogenic line as described
[32]. Final ‘‘mean CIMT’’ represents the average of 12
measurements made at end diastole, corresponding to distances
between lumen-intima and media-adventitia interfaces on both
sides, at the far and near arterial wall at 3 points within a 1.5-cm
segment immediately caudal to carotid bulb. ‘‘Maximal CIMT’’
represents the maximal value of the 12 measurements. Wall
thickness was measured outside atherosclerotic plaques (if present).
Coronary calcification. Coronary calcium CT examina-
tions were acquired on a GE LightSpeed
TM QXi, LightSpeed 16,
LightSpeed 16 Pro or VCT multidetector scanners of 4, 16 and 64
detector rows respectively. Analysis was performed using GE
SmartScore PRO
TM Coronary Artery Calcification Scoring
software on a GE Advantage Windows workstation version 3.1–
4.1 (GE Medical Systems, Milwaukee, WI). Prior to scanning, a 3-
lead EKG was applied to patients for gating and the signal
optimized. Anteroposterior and lateral scout images localized the
heart. Images were obtained at 2.5 mm collimation from cardiac
apex to base in cine mode with gantry rotation time of 0.35–0.6
seconds during a single breath-hold using a 25 cm field of view,
120 kVp and mA between 250 and 550 depending on patient size,
at end diastole. From overlapping images series, the least motion-
affected image within each scan group was selected automatically
for calcification scoring. SmartScore computed the calcium score
using standardized scoring techniques [33]. Generated scores were
the AJ-130 total calcium and the volume scores.
Circulating markers of vascular damage. Soluble mono-
cyte chemoattractant protein-1 (MCP-1), intercellular adhesion
molecule-I (ICAM-1), vascular cellular adhesion molecule-1
(VCAM-1), tissue factor (TF), vascular endothelial growth factor
(VEGF) (R&D systems, Minneapolis, MN); von Willebrand factor,
plasminogen activator inhibitor-1 (PAI-1) and tissue plasminogen
activator (TPA) (American Diagnostica, Stamford, CT) were
quantified by ELISA. High sensitivity CRP (hsCRP) was
quantified by ultra-sensitive rate immunonephelemetric method
(Dade-Behring, Marburg, Germany).
Serum type I IFN activity. Control and lupus serum was
assayed for the capacity to induce IFN-inducible genes (IFIGs) on
epithelial cell lines using a validated bioassay [34], previously used
by us [12]. Individuals with recent infections were excluded. CRP
and white cell counts were used to exclude subclinical infection.
Induction of IFIGs (IFI44, IFI44L, MX-1, IFIT1 and PRKR)o n
HeLa cells was quantified by real-time PCR [12]. Samples were
normalized to media alone after normalization to house-keeping
gene HPRT-1 and results reported as fold induction/media.
Other measures. CVD family history was considered
positive if a first-degree relative had a CV event at age ,55 or
65 years for male and female relatives, respectively. Lipids, CBC,
urine analysis, serum chemistry and homocysteine were quantified
at University of Michigan Central Laboratories. C3 and C4 were
measured using immunoturbidimetric methodology (Roche Diag-
nostics, Indianapolis, IN); anti-dsDNA by Farr radioimmunoassay
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IgM anticardiolipin and IgG, IgM and IgA anti-b-2 glycoprotein-I
Abs by ELISA and lupus anticoagulant (LA) by dilute Russell viper
venom test (American Diagnostica). SLE patients underwent
determinations of antiphospholipid antibodies and LA at least
twice; among patients with positive values at baseline, a second
determination at least 6 weeks apart was performed.
Statistical Methods
Summary statistics were computed for continuous measures as
mean 6 standard deviation or median (interquartile range, IQR) if
the distribution was skewed, and for categorical variables as
frequency and proportion (%). Variables were assessed for
normality and log-transformed if needed. Pearson or Spearman’s
rank correlations were used to examine associations between
continuous variables. Correlation results were adjusted for
multiple comparisons using Holm’s method [35]. Two sample t
tests or Kolmogorov-Smirnov testing were used for comparison of
continuous variables between groups, and the Chi-square test for
comparison of proportions.
IFIG data. We first standardized each of the five IFIGs using
their respective means and variances, so that the measurements
had the same scale. Our primary analysis utilized principal
component analysis (PCA) to combine the five standardized IFIGs
together in a few linear combinations, in order to (a) avoid multi-
collinearity between the IFIGs, (b) simultaneously account for the
majority of the total system variability in the five IFIGs, and (c)
reduce the number of parameters to estimate in the model. Since
the generated principal components are orthogonal to one
another, they can be modeled together without multi-collinearity
issues that would be encountered by simultaneous modeling the
five raw IFIG variables.
Univariate and multivariable linear regression were used to
examine the association of principal components generated from
the PCA and other predictor variables on the outcomes of FMD
and CIMT; zero-inflated Poisson (ZIP) regression was utilized for
the outcome of coronary calcification score due to the large
proportion of zero values for this outcome variable. Main effects,
as well as their interactions with SLE/control status, were included
in the multivariable models. Variables that we adjusted for in the
multivariable modeling included Framingham score, hsCRP,
PAI/TPA, tissue factor, SLE disease duration, and current
medication use (prednisone, antimalarials, statins, immunosup-
pressives). Because the PCA components of IFIGs were of our
main interest, we made the a priori decision to retain them in the
models regardless of significance. For non-PCA covariates (eg,
traditional CV risk factors and medications), we removed variables
that were strongly correlated to one another to prevent collinearity
issues. PCA components’ interactions with SLE case/control status
found to be non-significant at the 0.10 level were removed from
the models during the model building process. P values ,0.05 in
the final models were considered statistically significant. All
statistical analyses were performed using SAS 9.2 and R software.
Results
Participant Characteristics
A total of 95 SLE patients and 38 controls were included in this
study. Patients and controls were similar in terms of race/
ethnicity, traditional CV risk factors (including Framingham
score), and CVD family history. A small proportion of SLE
patients were positive for antiphospholipid antibodies (antic-
ardiolipin, lupus anticoagulant, and/or beta2-glycoprotein I)
(Table 1). Concomitant therapies for SLE patients included:
prednisone in 58 patients (61.1%, mean dose 9.268.2 mg/day);
antimalarials in 59 (62.1%); methotrexate in 8 (8.4%); azathio-
prine in 10 (10.5%); mycophenolate mofetil in 21 (22.1%);
cyclophosphamide in 4 (4.2%). Forty-four patients (46.3%) were
on NSAIDS and/or aspirin; and 8 (8.4%) were on a statin. When
compared to controls, SLE patients had decreased brachial artery
FMD (4.064.7 patients vs 5.764.1 controls; p=0.05), indicating
decreased endothelial function. There were no significant differ-
ences in CIMT or coronary calcification at study enrollment
between SLE and controls (Table 1).
Association of Serum IFN Activity with Surrogate Markers
CVD
In our study population, levels of the five individual IFIGs were
not statistically different between SLE patients and controls,
although MX-1 and IFI44 levels were higher among lupus patients
[median (IQR) expression levels: 4.4 (0.4, 48.5) in SLE versus 0.9
(0.3, 17.0) in controls; 5.3 (0.9, 55.4) in SLE versus 4.0 (0.7, 49.0)
in controls, respectively]. Consistent with previous publications
[19,36,37], there was considerable variability and a wide range of
IFIG values.
From the PCA on IFIGs, we found that the first three principal
components explain 97.1% of the variance information in the
original five IFIGs. Therefore, these three principal components
were used in the multivariable modeling. Figure 1 shows the
principal component factor loadings for the first two principal
components, which visually depicts IFIG groupings within the first
two principal components. The x-axis of Figure 1 is the principal
component factor loading (which is the coefficient for each IFIG in
the linear combination as the principal component) for the first
principal component. As shown, the x-axis of MX-1, IFI44L,
IFIT1, and IFI44 are very close to each other, while the one for
PRKR is very close to 0. As such, the first principal component is
a linear combination of the five IFIGs with the coefficients for the
first four being about the same and PRKR’s coefficient being about
0. Therefore, the first component can be interpreted as
approximately the sum of information from MX-1, IFI44L, IFIT1,
and IFI44 (<IFIT1+IFI44+MX-1+IFI44L). Similarly, the y-axis in
Figure 1 is the principal component factor loadings for the second
principal component, where we see the loading for PRKR is still
close to 0, while those of MX-1, IFI44L, IFIT1, and IFI44 have
about the same absolute values but the first two are negative and
the latter two are positive. Therefore, the second component can
be interpreted as approximately the difference between the sum of
IFIT1 and IFI44 and the sum of MX-1 and IFI44L [<(IFIT1+I-
FI44)2(MX-1+IFI44L)]. Further (not shown in Figure 1), the third
component has factor loadings for IFIGs all very close to 0 except
PRKR, and thus can be interpreted approximately as PRKR by
itself (<PRKR). Data from separate multivariable models for each
CVD surrogate outcome are summarized below; the regression
coefficients and 95% CIs for the PCA approach are presented in
Table 2. The analyses included both cases and controls for
CIMT and FMD, while the multivariable modeling for coronary
calcification was restricted to SLE group, since there were too few
controls with positive calcification scores to enable meaningful
inclusion for that outcome.
FMD. The association between FMD and the first three
components derived from the IFIG PCA were examined. Based on
the multivariable modeling, a 100 unit increase in the expression
level of component 3 (<PRKR) was associated with an average
decrease in FMD (expressed as % change of the brachial artery
diameter in response to reactive hyperemia) of 12.4 units (p,0.05),
when controlling for Framingham score, disease duration, and
baseline medication use of prednisone, antimalarial, and statins
Interferons and Cardiovascular Disease in Lupus
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depressed FMD (b coefficient 20.14; p=0.04), while the
remainder of the variables in the model were not associated with
FMD. Additional modeling, controlling for hsCRP, PAI1/TPA,
and tissue factor, yielded similar results and results from models
excluding medication use were also similar (data not shown).
These results indicate that enhanced serum IFN activity is
associated with decreased endothelial function in SLE patients
and controls.
CIMT. When mean CIMT was modeled as the outcome,
significant associations with the IFIG components 1 (<IFIT1+I-
FI44+MX-1+IFI44L) and 2 [<(IFIT1+IFI44)2(MX-1+IFI44L)]
were observed. In the multivariable model (see Table 2),
a 100 unit increase in the expression level of component 1 was
associated with a statistically significant increase of the mean
CIMT for SLE cases by 0.02 mm (p,0.01) when controlling for
all other variables (Framingham score, disease duration, and
baseline medication use of prednisone, antimalarial, and statins).
This association is not statistically different for the controls. A
100 unit increase in the expression level of component 2 was
associated with a statistically significant increase of the mean
CIMT for SLE cases by 0.03 mm (p,0.01). In contrast, for
Table 1. Baseline characteristics for SLE patients and controls.
Variable
SLE (n=95) Mean6SD or
Median (IQR) or No. (%)
CONTROLS (n=38) Mean6SD
or Median (IQR) or No. (%) P value
Females 95 (97.9%) 38 (100%) NS
Age (years) 37.669.1 39.3610.2 NS
Race NS
White 80 (84.2%) 34 (89.5%)
Black 12 (12.6%) 1 (2.6%)
Other 3 (3.2%) 3 (7.9%)
Framingham score 2.866.1 3.766.5 NS
BMI (kg/m
2) 25.065.3 27.366.1 NS
Systolic BP (mmHG) 119.6615.5 124.3613.9 NS
Diastolic BP (mmHG) 73.6610.6 72.7613.9 NS
Total cholesterol (mg/dl) 188.1647.4 198.6647.1 NS
Triglycerides (mg/dl) 89 (62, 134) 82 (66, 114) NS
High density lipoproteins (mg/dl) 60.5 (50, 74) 58 (46, 66) NS
Low density lipoproteins (mg/dl) 98 (80, 125) 110 (91, 130) NS
Family history of CVD 23 (24.5%) 12 (31.6%) NS
Homocysteine (umol/L) 7 (6, 10) 6 (5, 7.5) NS
hsCRP 1.3 (0.7, 3.6) 2.4 (0.9, 5.8) 0.05
TPA/PAI-1 2.4 (1.2, 4.2) 3.0 (1.6, 4.7) NS
Tissue Factor 127.7 (90.5, 168.3) 112.7 (72.1, 179.8) NS
SLE-specific measures
SLEDAI score 4 (0, 6) – –
Damage index 0 (0, 1) – –
PGA (0–3 visual analog scale) 0.1 (0, 0.5) – –
aCL - IgG
{ 4 (4.2%) – –
aCL - IgM
{ 2 (2.1%) – –
Lupus anticoagulant
{ 11 (11.6%) – –
anti-b2GPI - IgG
{ 1 (1.1%) – –
anti-b2GPI - IgM
{ 4 (4.2%) – –
anti-b2GPI - IgA
{ 7 (7.4%) – –
CVD surrogates
FMD (% change) 4.064.7 5.764.1 0.05
Mean CIMT (mm) 0.5860.11 0.5760.12 NS
Maximal CIMT (mm) 0.69 (0.59, 0.82) 0.65 (0.60, 0.77) NS
Coronary calcification scor
Proportion positive (score .0) 22/95 (23.2%) 8/38 (21.1%) NS
Score among positives 2.5 (1, 73) 10.5 (2, 28)
SD: standard deviation; IQR: interquartile range; CIMT: carotid intima media thickness; aCL: anticardiolipin antibodies; anti-b2GPI: beta2-glycoprotein I; PGA: physician
global assessment, BP: blood pressure; BMI: body mass index; NS: not significant; FMD: flow mediated dilatation.
{Antiphospholipid antibodies considered positive if positive on $2 occasions.
doi:10.1371/journal.pone.0037000.t001
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such that for every 100 unit increase in the expression level of
component 2, there was a corresponding decrease in mean
CIMT of 0.17 mm (i.e., 20.17=0.0320.20; p,0.001). Among
the other variables in the model, the Framingham score was
positively associated with mean CIMT (b coefficient 0.01;
p,0.001) and antimalarial use was positively associated at
borderline statistical significance (b coefficient 0.05; p=0.05).
Additional multivariable models, controlling for hsCRP, PAI1/
TPA, and tissue factor, yielded similar results and results from
models excluding medication use were also similar (data not
shown).
As shown in Table 2, results for the outcome of maximal
CIMT were similar to those for mean CIMT. When controlling
for Framingham score, disease duration, and baseline medication
use of prednisone, antimalarial, and statins, components 1 and 2
were positively associated with maximal CIMT for the SLE cases,
whereby a 100 unit increase in expression of each of these
components was associated with statistically significant increases in
the log maximal CIMT of 0.04 log(mm) (p,0.05) and 0.07
log(mm) (p,0.05), respectively. For controls, component 2 was
negatively associated with the maximal CIMT, where a 100 unit
increase in expression for component 2 significantly decreased the
maximum log CIMT by 0.36 units (i.e., 20.36=2.43+0.07;
p,0.01). Conversely for controls, a statistically significant associ-
ation between component 3 (<PRKR) and maximal CIMT was
observed for controls, where a 100 unit increase in expression for
component 3 was associated with an increase in the log maximal
CIMT of 0.89 log(mm) (p,0.05). These results indicate that
enhanced serum IFN activity, as represented by components 1 and
2, is associated with increased CIMT in SLE, but that the
association between component 2 and CIMT was reversed in the
non-SLE controls. However, the positive association between
PRKR and maximal CIMT observed in controls further implicates
an independent role for PRKR since, as shown above, it was also
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Figure 1. Plot of the first two principal component loading
vectors. Each point represents one of the five IFIGs. Proximity of points
illustrates the groupings of the IFIGs with respect to the principal
components. The x-axis is the principal component factor loading for
the first principal component (representing the coefficient for each IFIG
in the linear combination as the principal component); the y-axis is the
principal component factor loading for the second principal compo-
nent. The first component can be interpreted approximately as the sum
of information from MX-1, IFI44L, IFIT1,a n dIFI44. The second
component can be interpreted approximately as the difference
between the sum of (IFIT1 and IFI44) and the sum of (MX-1 and IFI44L).
doi:10.1371/journal.pone.0037000.g001
Table 2. Results from multivariable regression models investigating the association between serum type I IFN activity and
measures of subclinical CVD.
SLE Cases & Controls SLE Cases Only
FMD
{ Mean CIMT
{ Maximal CIMT (log)
{ Calcification Score
{
b coeff (95% CI) b coeff (95% CI) b coeff (95% CI) b coeff (95% CI)
IFIG Comp 1
a 0.281 (20.269, 0.831) 0.019 (0.006, 0.031)** 0.035 (0.002, 0.067)* 20.868 (22.129, 0.393)
IFIG Comp 2
b 0.515 (20.224, 1.254) 0.033 (0.008, 0.058)* 0.072 (0.010, 0.135)* 20.868 (20.052, 1.788)
IFIG Comp 3
c 212.423 (223.888, 20.958)* 20.353 (20.880, 0.174) 20.711 (22.029, 0.607) 61.301 (57.222, 65.380)***
Control (vs. SLE) 2.489 (20.296, 5.274) 0.104 (0.009, 0.199)* 0.278 (0.040, 0.515)* –
Interactions
Comp 1 6Control – – – –
Comp 2 6Control – 20.206 (20.317, 20.094)*** 20.432 (20.710, 20.153)** –
Comp 3 6Control – 0.580 (20.032, 1.192) 1.602 (0.071, 3.132)* –
Principal components analysis was first utilized to combine data from five IFN-inducible genes (IFIGs) into three principal components (explaining 97.1% of the total IFIG
variation) that could be simultaneously included as independent variables in the multivariable models. Data are presented for separate multivariable models (separate
columns), according to outcome.
aPrincipal component 1 (<IFIT1+IFI44+MX-1+IFI44L);
bPrincipal component 2 [<(IFIT1+IFI44)2(MX-1+IFI44L)];




{controlled for Framingham score, disease duration, and current medication use of prednisone, antimalarial, and statin; additional modeling controlling for hsCRP, PAI1/
TPA, tissue factor, yielded similar results (data not shown).
{SLE only models adjusted for Framingham score, current medication use of prednisone, antimalarial, and statin, plus SLEDAI and PAI-1/TPA; additional modeling
including immunosuppressive use (cyclophosphamide, azathioprine, mycophenolate mofetil) yielded similar results (data not shown).
doi:10.1371/journal.pone.0037000.t002
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regards to association with CV measurements, in contrast to the
other four IFIGs examined in this study (IFIT1, IFI44, MX-1, and
IFI44L).
Coronary calcification. As noted above, modeling of
coronary calcification was restricted to SLE patients since only 8
controls had non-zero values for the coronary calcification score
outcome. 22 of the 95 SLE patients had non-zero calcification
scores. The zero-inflated Poisson (ZIP) regression modeling
includes two parts – the first of which is a logistic model where
the calcification score outcome is handled as a binary variable
(positive or negative) in the full SLE group of 95 patients, whereas
the second part is a Poisson model examining the calcification
score level as a continuous measure among the subset of 22
patients with a positive score. When examining the risk of having
a positive coronary calcification score (as a binary variable), we
found the Framingham score (OR 1.3, 95% CI 1.1, 1.5) and PAI-
1/TPA (OR 1.3, 95% CI 1.0, 1.6) were associated with a positive
coronary calcification score in the multivariable model. In the
second part of the ZIP modeling, which was restricted to the 22
SLE patients with positive coronary calcification scores, a statisti-
cally significant association between principal component 3
(<PRKR) and level of coronary calcification was detected when
controlling for all other variables in the model, whereby each
1 unit increase in expression of principal component 3 was
associated with a 1.8-fold increase in expected coronary calcifica-
tion score [i.e., exp(61.301/100)=1.8; p,0.001; the exponential of
the coefficient in the Poisson regression model represents the ratio
of the expected coronary calcification scores associated with
increase of the corresponding variable]. However, in this restricted
portion of the model, the Framingham score, PAI-1/TPA,
SLEDAI, and prednisone were all negatively associated with the
level of coronary calcification (p,0.01), while statin use was
positively associated (p,0.01). Additional modeling including
immunosuppressive use (cyclophosphamide, azathioprine, myco-
phenolate mofetil) yielded similar results (data not shown). These
results indicate that traditional risk factors, but not IFN serum
activity, are associated with risk of having a positive coronary
calcification score. However, among those SLE patients with
a positive coronary calcification score, the traditional risk factors
are negatively associated and IFN serum activity is positively
associated with the severity of coronary calcification. These results
may indicate the possibility of a differential effect of various risk
factors for the initial development and progression of calcification
in patients with SLE.
Discussion
In this study we demonstrate that, in a cohort of SLE patients
with on average low disease activity and without pre-existing
CVD, non-traditional risk factors are independently associated
with preclinical vascular damage. After controlling for known CV
risk factors, serum type I IFN activity is independently associated
with decreased FMD and with increased CIMT and coronary
calcification severity in SLE. These observations further support
the hypothesis that type I IFNs may play a pathogenic role in
premature CVD in SLE.
This study builds upon previous suggestions of a role for type I
IFNs in CVD [12,22], by refining the approach towards
examining IFIGs as a system. As recently noted by Reynier et
al., the common approach of calculating a binary ‘‘IFN score’’
(high versus low) based on average gene expression levels ignores
co-regulation of such IFN-related genes, which in turn can lead to
misclassification [38]. The high degree of collinearity between
IFIGs’ induction also precludes simultaneous modeling of the
individual genes. PCA enabled the transformation of the in-
dividual correlated IFIGs into a smaller number of uncorrelated
variables, the principal components, which account for as much of
the data variability as possible. We thus derived composite
measures of the five individual IFIGs without collinearity or
arbitrary, post hoc decisions regarding creation of a composite IFIG
measure or removal of outliers. The resulting variables represent-
ing IFIGs can be modeled simultaneously, while retaining as much
information as possible.
Results from our systems-based approach indicate that levels of
PRKR induction were independently associated with impaired
FMD in both cases and controls, increased maximal CIMT in
controls, and increased coronary calcification among SLE patients
(this last outcome could not be studied among controls due to few
having positive calcification scores). In contrast, the effects of the
other four IFIGs–MX-1, IFI44L, IFIT1, and IFI44– appear to
impact the vasculature in an orchestrated fashion. In particular,
induction of these IFIGs was associated with increased CIMT in
SLE patients, but decreased CIMT among controls. The basis for
this observed interaction between these IFIGs and case/control
status is unclear, and warrants further investigation. However, the
presence of such interactive effects supports the concept that the
excess CVD risk in SLE may be partially attributable to SLE-
specific factors. This finding of differential effects associated with
different IFIGs could indicate that various vascular territories
respond differently to immunologic insults; this is supported by
studies in the general population [39]. The observed differential
effects also underscore the need to follow an approach such as
PCA, as the use of a single binary summary score integrating data
from the various IFIGs would be an oversimplification and would
dilute results. Indeed, as an exploratory measure we calculated
a high versus low IFN score (a ‘‘high’’ score representing
individuals with at least 2 IFIGs above the 95
th percentile among
controls for each IFIG). We found that 15.8% of SLE patients and
7.9% of controls were classified as ‘‘high producers’’ according to
this classification. While we replicated the finding that CIMT was
associated with high IFN production in SLE patients, we did not
detect associations with endothelial dysfunction or coronary
calcification when using this binary classification.
While recent evidence suggests that type I IFNs could play a role
in ‘‘idiopathic’’ atherosclerosis in the general population, our
results underscore the utility of following a systems-based
approach to more specifically characterize the components of
the type I IFN pathway that may be involved in vascular damage.
Available data indicate that IFN-a levels are increased in
atherosclerotic plaque [40,41]. LDL-receptor deficient mice
exposed to recombinant IFN-a develop worsening hyperlipidemia
and atherosclerosis, while recent evidence points at a deleterious
role of another type I IFN, IFN-b, in murine atherosclerosis
[42,43]. IFN-a may play an immunostimulatory role in the
atherosclerotic plaque by enhancing vascular damage by T and
NK cells [40]. There is a potential association between type I IFNs
and platelet activation and foam cell formation [26,44], which
could enhance thrombogenicity and plaque deposition and
predispose to acute coronary syndromes.
Whether activation of the specific IFIGs directly induces
vascular effects, or whether type I IFN activation may impact
the vasculature via other pathways, remains to be identified.
However, the associations we detected are relevant to both
functional (FMD) and anatomic (CIMT, coronary calcification)
measures of subclinical CVD, and various stages in the natural
history of CVD. This raises the possibility of various targets and
windows for intervention.
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from the general population, according to same eligibility criteria
as SLE patients, rather than restricting them to ‘‘healthy’’
individuals. SLE patients were included irrespective of disease
severity, rather than restricting to cases at the higher end of the
spectrum in terms of severity. Thus, the distributions of traditional
CV risk factors and potential confounders were similar between
lupus and controls, and such comparability in known CV risk
factors enabled more focused investigation of novel risk factors.
Further, two major CVD risk factors – smoking and diabetes –
were exclusion criteria and thus did not complicate the in-
terpretation of our results. Various soluble markers (e.g., adhesion
molecules, hsCRP) reported as associated with vascular damage in
other conditions did not correlate with atherosclerosis or
endothelial dysfunction in our population.
Differences between our findings and other studies [45,46] may
be related to patient population variations, including race/
ethnicity, age, and disease activity, or to the CV surrogate
outcomes evaluated. With the majority of our population being
female (reflecting the underlying preponderance of SLE among
women), our findings are not directly comparable to those from
studies involving a larger proportion of males. Likewise, our
population was relatively homogeneous in terms of race/ethnicity,
potentially limiting generalizability of our results to non-white
populations. SLE patients in this study, with overall low disease
activity and low Framingham scores, had significantly impaired
FMD versus controls, and non-significantly increased CIMT and
coronary calcification. The lack of significant differences between
cases and controls for CIMT and coronary calcification may
reflect the relatively young age of the study population, which was
by design in order to avert the confounding effects of the
postmenopausal state and comorbidities on endothelial function.
Low disease activity may have also contributed to these findings.
Longitudinal research will be necessary to characterize patterns
of IFIG induction over time (e.g., chronic versus acute/transient
activation) in both SLE and non-SLE populations, and to
elucidate factors underlying the detected interaction between
IFIGs and case-control status. Further, the impact of treatments,
including immunosuppressives and statins, on IFIG induction
needs to be studied in detail. In an observational study such as
ours, it is difficult to directly assess the impact of medications, and
confounding by indication is a concern. Therefore, it would be
interesting to evaluate type I IFN signatures in ancillary studies to
randomized controlled trials. It will also be important to examine
the role of type I IFNs in cohorts of patients with more severe
lupus manifestations, as the patient population we studied was
well-controlled. Future studies need to distinguish the roles of type
I IFN pathway components, and at various stages in the natural
history of CVD.
In conclusion, type I IFNs are independently associated with
both functional and anatomic markers of subclinical CVD. Our
results support the hypothesis that type I IFNs promote
accelerated atherosclerosis in SLE, and that excess CVD risk in
SLE patients is in part due to factors that operate uniquely in SLE
patients as opposed to controls. Future studies should address if
blockade of type I IFN pathways early in the natural history of
disease leads to a reduction of CVD in SLE and, potentially, in
other autoimmune diseases.
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